Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study was undertaken to evaluate bone response in metastatic prostate cancer patients
treated with Enzalutamide with or without Zoledronic Acid in combination with luteinizing
hormone-releasing hormone (LHRH) analogue with the use of Whole Boby (WB) DW-MRI.
Phase:
Phase 2
Details
Lead Sponsor:
Azienda Ospedaliera Spedali Civili di Brescia Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia